Dr. Adrian G. Sacher
Claim this profilePrincess Margaret Cancer Centre
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
8 reported clinical trials
20 drugs studied
Area of expertise
1Lung Cancer
Stage IV
Stage III
PD-L1 positive
2Non-Small Cell Lung Cancer
Stage IV
Stage III
PD-L1 positive
Affiliated Hospitals
Clinical Trials Adrian G. Sacher is currently running
Pembrolizumab
for Lung Cancer
BR36 will evaluate the potential clinical benefit of tailoring immunotherapy treatment based on ctDNA molecular response in non-small cell lung cancer.
Recruiting1 award Phase 2 & 318 criteria
Adoptive Cell Therapy
for Cancer
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Recruiting1 award Phase 1
More about Adrian G. Sacher
Clinical Trial Related6 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Adrian G. Sacher has experience with
- Pembrolizumab
- Atezolizumab
- Bevacizumab
- CfDNA Blood Test
- Ipilimumab, Nivolumab
- Platinum-based Chemotherapy
Breakdown of trials Adrian G. Sacher has run
Lung Cancer
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- Pembrolizumab for Lung Cancer
- Nivolumab + Ipilimumab for Lung Cancer
Non-Small Cell Lung Cancer
Cancer
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- Novel Drug Regimens for Lung Cancer
- Adoptive Cell Therapy for Cancer
Tumors
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- Novel Drug Regimens for Lung Cancer
- Adoptive Cell Therapy for Cancer
Liver Metastases
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Adrian G. Sacher specialize in?
Adrian G. Sacher focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Adrian G. Sacher currently recruiting for clinical trials?
Yes, Adrian G. Sacher is currently recruiting for 3 clinical trials in Toronto Ontario. If you're interested in participating, you should apply.
Are there any treatments that Adrian G. Sacher has studied deeply?
Yes, Adrian G. Sacher has studied treatments such as Pembrolizumab, Atezolizumab, Bevacizumab.
What is the best way to schedule an appointment with Adrian G. Sacher?
Apply for one of the trials that Adrian G. Sacher is conducting.
What is the office address of Adrian G. Sacher?
The office of Adrian G. Sacher is located at: Princess Margaret Cancer Centre, Toronto, Ontario M5G1X6 Canada. This is the address for their practice at the Princess Margaret Cancer Centre.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.